Simple Clinical, Laboratory Parameters Predict Mortality in Pancreatic Adenocarcinoma
the Cancer Therapy Advisor take:
The Khorana score and other associated factors of early mortality help identify high-risk patients after surgical resection for pancreatic cancer, according to an article published online in Cancer.
The cohort study examined 334 patients with a median age of 67 years who underwent surgical resection for pancreatic cancer between January 2006 and June 2013. Of the enrolled patients, 50% were female and 86% were white.
The primary tumor site was the pancreatic head for 73% of patients. Of the tumors, 67% were T3 and 63% were N1.
High-risk patients were defined as having a Khorana score greater than three. Out of the 334 patients, 152 (47%) were considered to be high risk. The median Khorana score was determined to be two.
The two major adjunctive treatments for patients included chemotherapy and radiotherapy (70% and 40%, respectively).
There was an observed difference of the postoperative 30 day mortality rate and the 6-month mortality rate between patients who were not determined to be high risk and those who were.
For those patients who weren’t high-risk, the 30-day mortality rate was 0.9% and the 6-month mortality rate was 9.4%.
High-risk patients experienced significantly higher mortality rates, with 13.4% having 30-day and 5.6% experiencing 6-month mortality (P=0.02).
The study suggests that future research focus on preoperative interventions for patients who are considered high-risk for early mortality.
The Khorana score and other factors of early mortality help identify high-risk patients after surgical resection for pancreatic cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM